An overview of cyclophosphamide development and clinical applications.
about
Xenobiotic effects on ovarian preantral folliclesRapid induction of apoptosis during Kinesin-5 inhibitor-induced mitotic arrest in HL60 cells.Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cellsDrug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy.Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complexInflammasomes are important mediators of cyclophosphamide-induced bladder inflammation.Epigenetic programming in the preimplantation rat embryo is disrupted by chronic paternal cyclophosphamide exposure.Effects of cell cycle inhibitors on tau phosphorylation in N2aTau3R cells.Paternal cyclophosphamide exposure induces the formation of functional micronuclei during the first zygotic divisionImpact of environmental exposures on ovarian function and role of xenobiotic metabolism during ovotoxicityDissecting the impact of chemotherapy on the human hair follicle: a pragmatic in vitro assay for studying the pathogenesis and potential management of hair follicle dystrophy.Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.Circadian clock genes as modulators of sensitivity to genotoxic stress.Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitisThe constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignanciesThe influence of amifostine administration prior to cyclophosphamide on in vitro maturation of mouse oocytes.Oxazaphosphorine bioactivation and detoxification The role of xenobiotic receptors.Role of carnitine in cancer chemotherapy-induced multiple organ toxicity.Genetic Susceptibility to ANCA-Associated Vasculitis: State of the Art.Introducing a new class of N-phosphoryl ynamides via Cu(I)-catalyzed amidations of alkynyl bromides.Investigating critical genes and gene interaction networks that mediate cyclophosphamide sensitivity in chronic myelogenous leukemiaReversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12.Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.Amelioration of the cyclophosphamide induced genotoxic damage in mice by the ethanolic extract of Equisetum arvenseGreen tea infusion improves cyclophosphamide-induced damage on male mice reproductive system.Short-term comparative study of the cyclophosphamide genotoxicity administered free and liposome-encapsulated in mice.Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses.The dose of cyclophosphamide for treating paraquat-induced rat lung injury.Cyclophosphamide-evoked heart failure involves pronounced co-suppression of cytoplasmic thioredoxin reductase activity and non-protein free thiol level.Genetic background influences susceptibility to chemotherapy-induced hematotoxicity.The Natural Carotenoid Crocetin and the Synthetic Tellurium Compound AS101 Protect the Ovary against Cyclophosphamide by Modulating SIRT1 and Mitochondrial Markers.The potential use of physical resilience to predict healthy aging.Protective Effect of Kolaviron on Cyclophosphamide-Induced Cardiac Toxicity in Rats
P2860
Q24634884-114C048B-94FC-4369-9345-7AF5141EF082Q30503448-39F310A0-80F0-48A8-A63D-FE4C2B3E2EA4Q33638864-2D874EDD-CC38-48FC-802C-FB0616CC3955Q33646358-2B2E9DDC-889C-4D7A-8E76-471DF46D09DCQ33783874-C6800DFF-2AC2-4645-B794-2E4ADCC483A0Q33816592-6FEEE3ED-9290-4FC2-86F0-E38B6F343A4CQ33833518-390D7440-ECB0-4972-8526-8746366A7FFAQ33955039-09B12847-59E8-440B-9049-C895C272A9A1Q34081617-FF7DEBD9-0723-4CFE-A797-41F88F889AC8Q35985194-DD0F99FD-9227-4030-A772-F2153959A9F0Q36007390-7E29AFD4-F930-4D47-8578-FA23E70CF0ABQ36101917-E232F05F-17B1-4D4B-B0F1-4BF9E94C57F8Q36139993-712FF4DA-C0B5-477E-B8BA-288DEB79BEFEQ36336024-22E8345D-2A54-40F5-94F4-0C83667288FEQ36529490-8E595A8E-8546-45D5-BF2B-C7ABADC1B754Q37049967-9EEA389B-4C12-4ED0-8335-261ED31DC0A9Q37386327-4B40557C-93C7-4173-8ADE-B1A007C8533FQ38130229-37151D56-B250-4BC1-B878-E517616C5AD6Q38276417-D91E5FC8-3609-42D7-948F-2042587ACE3DQ38366462-88174A60-6876-4260-99A2-C5D4C085FD15Q38432973-F1D5EB9D-A365-46E2-8C14-A53167560192Q41132577-563667C4-0C90-42DC-B7B8-682A83CC0E2CQ41677104-8745752D-896C-4753-8514-C0D6C753871CQ41679054-4A1913D2-9E61-4492-AC68-79AE30A6CA55Q41680686-939A666A-A8B7-4177-98D8-3F5B1A9B18C0Q41847966-32492067-C541-4922-B64D-4F75E0D5A644Q42937380-6872F341-4C97-4F84-AE10-5FCDE293EBDBQ43090747-246676C8-40E0-49A8-B5D6-5A68CE42C8ABQ43184050-2DF52A61-9982-42EB-A883-626AE81FD48FQ47094464-F2E6BF86-D26D-44A0-B888-E4A87ECF5A95Q47094970-1FE29B9E-3081-401F-B24F-122A799481AEQ47105123-6B7CCFB1-02EB-450E-821E-C4099BF30DCAQ57931690-CEB91556-225F-4468-9E6E-31A13FECFA83
P2860
An overview of cyclophosphamide development and clinical applications.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
An overview of cyclophosphamide development and clinical applications.
@ast
An overview of cyclophosphamide development and clinical applications.
@en
type
label
An overview of cyclophosphamide development and clinical applications.
@ast
An overview of cyclophosphamide development and clinical applications.
@en
prefLabel
An overview of cyclophosphamide development and clinical applications.
@ast
An overview of cyclophosphamide development and clinical applications.
@en
P1476
An overview of cyclophosphamide development and clinical applications
@en
P2093
O M Colvin
P304
P577
1999-08-01T00:00:00Z